AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

23.05.22	AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting (PR Newswire)
23.05.22	AbbVie:CHMP Recommends European Commission Approval Of Upadacitinib For Ulcerative Colitis Treatment (RTTNews)
23.05.22	CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis (PR Newswire)
20.05.22	AbbVie Submits NDA For ABBV-951 To FDA For Treatment Of Advanced Parkinson's Disease (RTTNews)
20.05.22	AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease (PR Newswire)
16.05.22	AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week® (PR Newswire)
16.05.22	AbbVie Receives Option To License Certain IL-2 Muteins, Including CUG252, From Cugene (RTTNews)
16.05.22	AbbVie and Cugene Announce Collaboration in Autoimmune Diseases (PR Newswire)
14.05.22	ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
12.05.22	AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses (PR Newswire)
12.05.22	AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education (PR Newswire)
11.05.22	AbbVie Announces Positive Topline Results From U-ENDURE Phase 3 Study Evaluating Upadacitinib (RTTNews)
11.05.22	Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease (PR Newswire)
02.05.22	Rosen, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
30.04.22	FDA Approves AbbVie's Rinvoq To Treatment Active Ankylosing Spondylitis (RTTNews)
29.04.22	RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis (PR Newswire)
29.04.22	AbbVie Shares Hurt On Reduced Earnings Outlook (RTTNews)
29.04.22	AbbVie Q1 Income Rises (RTTNews)
29.04.22	AbbVie Trims FY22 Adj. EPS Outlook - Update (RTTNews)
29.04.22	AbbVie Reports First-Quarter 2022 Financial Results (PR Newswire)
28.04.22	Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (PR Newswire)
28.04.22	Ausblick: AbbVie stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
27.04.22	AbbVie: Health Canada Approves VRAYLAR - Quick Facts (RTTNews)
25.04.22	TOP RANKED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
20.04.22	Dragonfly Therapeutics Expands Collaboration With AbbVie To Develop Novel Immunotherapies (RTTNews)
20.04.22	Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases (PR Newswire)
20.04.22	AbbVie Walks Away From Alpha-synuclein Collaboration With BioArctic (RTTNews)
19.04.22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (PR Newswire)
18.04.22	ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
15.04.22	Erste Schätzungen: AbbVie vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
14.04.22	Novartis-Aktie im Plus: Sandoz verkauft Nachahmer-Augentropfen in den USA (AWP) Die Generika-Sparte von Novartis wird künftig das günstigere Nachahmer-Präparat von AbbVies Augentropfen Combigan in den USA verkaufen.» mehr
14.04.22	AbbVie to Host First-Quarter 2022 Earnings Conference Call (PR Newswire)
14.04.22	Sandoz Launches Generic Version Of Eyedrop In U.S. For Patients With Ocular Hypertension (RTTNews)
14.04.22	AbbVie Announces Positive Results For Epcoritamab From Phase 1/2 Trial In Blood Cancer (RTTNews)
14.04.22	AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) (PR Newswire)
13.04.22	BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval (PR Newswire)
12.04.22	AbbVie : Phase 2 Study Of Navitoclax Combination Shows Anti-Fibrosis Activity In Rare Blood Cancer (RTTNews)
12.04.22	AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis (PR Newswire)
08.04.22	ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
05.04.22	Allergan Reveals Positive Phase 3 Results Of VUITY In Adults With Age-Related Blurry Near Vision (RTTNews)
05.04.22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with A... (PR Newswire)
29.03.22	AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting (PR Newswire)
21.03.22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting (PR Newswire)
16.03.22	RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
15.03.22	Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours (PR Newswire)
15.03.22	AbbVie, Scripps Join Hands To Develop Direct-acting Antiviral Treatments For Covid-19 (RTTNews)
15.03.22	AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19 (PR Newswire)
11.03.22	AbbVie, Gedeon To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases Treatment (RTTNews)
11.03.22	AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases (PR Newswire)
10.03.22	AbbVie: Phase 3 Study With Atogepant In Adult Patients With Chronic Migraine Meets Primary Endpoint (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten

06.05.24

S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude

26.04.24

Gewinne in New York: S&P 500 am Nachmittag fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten